EFS of the DUO System for Tricuspid Regurgitation (NCT05913908) | Clinical Trial Compass
RecruitingNot Applicable
EFS of the DUO System for Tricuspid Regurgitation
United States15 participantsStarted 2024-08-13
Plain-language summary
The study is an early feasibility study to measure individual patient clinical outcomes and effectiveness, evaluate the safety and function of the DUO Transcatheter Tricuspid Coaptation Valve System (DUO System).
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Presence of severe or greater tricuspid regurgitation as determined by the Echo Core Lab.
. Patient is symptomatic despite medical therapy.
. The local Site Heart Team determines the Patient is appropriate for transcatheter valve intervention.
. The Patient's anatomy is suitable in the judgment of the Patient Selection Committee.
. Age ≥18 years
. The Patient has been informed of the nature of the study and agrees to its provisions and has provided written Informed Consent.
Exclusion criteria
. Patient is currently participating in another clinical investigation that could affect the outcome of this trial.
. Any previous tricuspid valve intervention that would interfere with the placement of the investigational device.
. Moderate or greater tricuspid valve stenosis.
. Severe aortic, mitral and/or pulmonic valve stenosis and/or regurgitation